γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
γ‐Secretase inhibitors ( GSI s) are being actively repurposed as cancer therapeutics based on the premise that inhibition of NOTCH 1 signaling in select cancers is therapeutic. Using novel assays to probe effects of GSI s against a broader panel of substrates, we demonstrate that clinical GSI s are pharmacologically distinct. GSI s show differential profiles of inhibition of the various NOTCH substrates, with some enhancing cleavage of other NOTCH substrates at concentrations where NOTCH 1 cleavage is inhibited. Several GSI s are also potent inhibitors of select signal peptide peptidase ( SPP / SPPL ) family members. Extending these findings to mammosphere inhibition assays in triple‐negative breast cancer lines, we establish that these GSI s have different functional effects. We also demonstrate that the processive γ‐secretase cleavage pattern established for amyloid precursor protein ( APP ) occurs in multiple substrates and that potentiation of γ‐secretase cleavage is attributable to a direct action of low concentrations of GSI s on γ‐secretase. Such data definitively demonstrate that the clinical GSI s are not biological equivalents, and provide an important framework to evaluate results from ongoing and completed human trials with these compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain
De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., et al. (1999) · Nature · doi:10.1038/19083 · Cited by 2,100
Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia
Joutel, A., Corpechot, C., Ducros, A., Vahedi, K., Chabriat, H., Mouton, P., Alamowitch, S., Domenga, V., Cécillion, M., Maréchal, E., et al. (1996) · Nature · doi:10.1038/383707a0 · Cited by 2,068
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921 · cited 1×
“A number of GSIs have been developed that effectively inhibit c-secretase cleavage in humans since c-secretase was identified as a therapeutic target in Alzheimer’s disease (AD) (Haass et al, 1992; Shoji et al, 1992).”
BackgroundProduction of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“A number of GSIs have been developed that effectively inhibit c-secretase cleavage in humans since c-secretase was identified as a therapeutic target in Alzheimer’s disease (AD) (Haass et al, 1992; Shoji et al, 1992).”
BackgroundSelf-citationA Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.-C., Chanthery, Y., Kowalski, J., Watts, R. J., Callahan, C., Kasman, I., et al. (2006) · Nature · doi:10.1038/nature05313 · Cited by 986 · cited 1×
“Monoclonal antibodies (Noguera-Troise et al, 2006; Ridgway et al, 2006; Hoey et al, 2009; Jenkins et al, 2012), antisense or RNA interference (Wang et al, 2006; Pietras et al, 2011), receptor decoys (Smas et al, 1997; Small et al, 2001; Funahashi et al, 2008; Kangsamaksin et al, 2015), and…”
BackgroundAph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex
De Strooper, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00205-8 · Cited by 965 · cited 1×
“…of c-secretase, and three accessory proteins, anterior pharynx-defective 1 (APH-1), nicastrin, and presenilin enhancer protein 2 (PEN2) are also required to complete the c-secretase complex (De Strooper, 2003; Edbauer et al, 2003; Kimberly et al, 2003; Takasugi et al, 2003; Wolfe & Kopan, 2004).”
BackgroundThe secretases: enzymes with therapeutic potential in Alzheimer disease
De Strooper, B., Vassar, R., & Golde, T. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.218 · Cited by 799
Self-citationTakami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M., Funamoto, S., & Ihara, Y. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2362-09.2009 · Cited by 498
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
CAR T cell therapies for patients with multiple myeloma
Mikkilineni, L., & Kochenderfer, J. N. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0427-6 · Cited by 270
Targeting Notch in oncology: the path forward
Majumder, S., Crabtree, J. S., Golde, T. E., Minter, L. M., Osborne, B. A., & Miele, L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00091-3 · Cited by 270
Self-citationTranscriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer
Zhang, Z., Lee, J.-H., Ruan, H., Ye, Y., Krakowiak, J., Hu, Q., Xiang, Y., Gong, J., Zhou, B., Wang, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12543-5 · Cited by 263
Natural products: An upcoming therapeutic approach to cancer
Dutta, S., Mahalanobish, S., Saha, S., Ghosh, S., & Sil, P. C. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.04.012 · Cited by 259
Metadata
- Authors
- Ran, Y., Hossain, F., Pannuti, A., Lessard, C. B., Ladd, G. Z., Jung, J. I., Minter, L. M., Osborne, B. A., Miele, L., & Golde, T. E.
- Venue
- EMBO Molecular Medicine
- Published
- 2017-05-24
- Volume
- 9
- Issue
- 7
- Pages
- 950-966
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2618466363
- Cited by
- 128
- References
- 9
- FWCI
- 10.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct. https://app.cochat.ai/papers/10.15252/emmm.201607265
- The paper
- Ran, Y., Hossain, F., Pannuti, A., Lessard, C. B., Ladd, G. Z., Jung, J. I., Minter, L. M., Osborne, B. A., Miele, L., & Golde, T. E. (2017). γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201607265
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.